Intensive Care Patients from the First COVID-19 Wave: One-Year Survival after Tocilizumab Treatment

Introduction: An infection by COVID-19 triggers a dangerous cytokine storm, so tocilizumab has been introduced in Italy as an agent blocking the cytokine storm. This paper aims to describe the one-year survival of ICU patients treated with tocilizumab. Methods: This observational study enrolled all...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Gabriele Melegari, Enrico Giuliani, Chiara Dallai, Lucia Veronesi, Elisabetta Bertellini, Suela Osmenaj, Alberto Barbieri
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	COVID-19 cytokine storm medication COVID-19 post-infection symptoms Medicine R
Acceso en línea:	https://doaj.org/article/60a55ff4f2da4522a9a232afed5a43c3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:60a55ff4f2da4522a9a232afed5a43c3
record_format	dspace
spelling	oai:doaj.org-article:60a55ff4f2da4522a9a232afed5a43c32021-11-25T18:08:14ZIntensive Care Patients from the First COVID-19 Wave: One-Year Survival after Tocilizumab Treatment10.3390/jpm111112342075-4426https://doaj.org/article/60a55ff4f2da4522a9a232afed5a43c32021-11-01T00:00:00Zhttps://www.mdpi.com/2075-4426/11/11/1234https://doaj.org/toc/2075-4426Introduction: An infection by COVID-19 triggers a dangerous cytokine storm, so tocilizumab has been introduced in Italy as an agent blocking the cytokine storm. This paper aims to describe the one-year survival of ICU patients treated with tocilizumab. Methods: This observational study enrolled all patients confirmed to be infected by COVID-19 who were admitted to the ICU in our center. We offered tocilizumab to all non-septic patients if they did not present any contraindications. Results: We enrolled 68 ICU patients in our center on 72 occasions during the enrollment period; we excluded four patients due to study criteria. The one-year mortality hazard ratio of treated patients was 0.64, with a confidence interval of 0.31 to 1.19, with <i>p</i> = 0.169. Among the survivors, 32 of 35 patients answered the phone interview (14 patients in the treated group and 18 in the untreated group); overall, the effect of COVID-19 on quality of life was 58.14%. These effects were lower in the tocilizumab group, with <i>p</i> = 0.016 *. Conclusions: Our observational data follow the most relevant largest trial. Patients treated with tocilizumab had lower rates of new-onset symptoms later COVID-19 ICU hospitalizations. As reported by recent medical literature, the presence of these symptoms suggests that a follow-up program for these types of patients could be useful.Gabriele MelegariEnrico GiulianiChiara DallaiLucia VeronesiElisabetta BertelliniSuela OsmenajAlberto BarbieriMDPI AGarticleCOVID-19cytokine storm medicationCOVID-19 post-infection symptomsMedicineRENJournal of Personalized Medicine, Vol 11, Iss 1234, p 1234 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	COVID-19 cytokine storm medication COVID-19 post-infection symptoms Medicine R
spellingShingle	COVID-19 cytokine storm medication COVID-19 post-infection symptoms Medicine R Gabriele Melegari Enrico Giuliani Chiara Dallai Lucia Veronesi Elisabetta Bertellini Suela Osmenaj Alberto Barbieri Intensive Care Patients from the First COVID-19 Wave: One-Year Survival after Tocilizumab Treatment
description	Introduction: An infection by COVID-19 triggers a dangerous cytokine storm, so tocilizumab has been introduced in Italy as an agent blocking the cytokine storm. This paper aims to describe the one-year survival of ICU patients treated with tocilizumab. Methods: This observational study enrolled all patients confirmed to be infected by COVID-19 who were admitted to the ICU in our center. We offered tocilizumab to all non-septic patients if they did not present any contraindications. Results: We enrolled 68 ICU patients in our center on 72 occasions during the enrollment period; we excluded four patients due to study criteria. The one-year mortality hazard ratio of treated patients was 0.64, with a confidence interval of 0.31 to 1.19, with <i>p</i> = 0.169. Among the survivors, 32 of 35 patients answered the phone interview (14 patients in the treated group and 18 in the untreated group); overall, the effect of COVID-19 on quality of life was 58.14%. These effects were lower in the tocilizumab group, with <i>p</i> = 0.016 *. Conclusions: Our observational data follow the most relevant largest trial. Patients treated with tocilizumab had lower rates of new-onset symptoms later COVID-19 ICU hospitalizations. As reported by recent medical literature, the presence of these symptoms suggests that a follow-up program for these types of patients could be useful.
format	article
author	Gabriele Melegari Enrico Giuliani Chiara Dallai Lucia Veronesi Elisabetta Bertellini Suela Osmenaj Alberto Barbieri
author_facet	Gabriele Melegari Enrico Giuliani Chiara Dallai Lucia Veronesi Elisabetta Bertellini Suela Osmenaj Alberto Barbieri
author_sort	Gabriele Melegari
title	Intensive Care Patients from the First COVID-19 Wave: One-Year Survival after Tocilizumab Treatment
title_short	Intensive Care Patients from the First COVID-19 Wave: One-Year Survival after Tocilizumab Treatment
title_full	Intensive Care Patients from the First COVID-19 Wave: One-Year Survival after Tocilizumab Treatment
title_fullStr	Intensive Care Patients from the First COVID-19 Wave: One-Year Survival after Tocilizumab Treatment
title_full_unstemmed	Intensive Care Patients from the First COVID-19 Wave: One-Year Survival after Tocilizumab Treatment
title_sort	intensive care patients from the first covid-19 wave: one-year survival after tocilizumab treatment
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/60a55ff4f2da4522a9a232afed5a43c3
work_keys_str_mv	AT gabrielemelegari intensivecarepatientsfromthefirstcovid19waveoneyearsurvivalaftertocilizumabtreatment AT enricogiuliani intensivecarepatientsfromthefirstcovid19waveoneyearsurvivalaftertocilizumabtreatment AT chiaradallai intensivecarepatientsfromthefirstcovid19waveoneyearsurvivalaftertocilizumabtreatment AT luciaveronesi intensivecarepatientsfromthefirstcovid19waveoneyearsurvivalaftertocilizumabtreatment AT elisabettabertellini intensivecarepatientsfromthefirstcovid19waveoneyearsurvivalaftertocilizumabtreatment AT suelaosmenaj intensivecarepatientsfromthefirstcovid19waveoneyearsurvivalaftertocilizumabtreatment AT albertobarbieri intensivecarepatientsfromthefirstcovid19waveoneyearsurvivalaftertocilizumabtreatment
_version_	1718411561525051392

Intensive Care Patients from the First COVID-19 Wave: One-Year Survival after Tocilizumab Treatment

Ejemplares similares